To Evaluate the in Use Tolerance of E45 Eczema Repair Emollient in Babies and Children With (Very(Dry/Atopic Skin

NCT02857062 | Completed

• 1 other identifier: 09224-02
• Study Type: interventional
• Target: 34
• Locations: 0 countries
• Sites: N/A

Brief Summary

The investigation will evaluate, under dermatological control, the cutaneous in-use tolerance of E45 Eczema Repair Emollient with two or three times daily application, over a period of two weeks on children and babies with dry/atopic and very dry/atopic skin.

Conditions

Atopic Dermatitis / Eczema

Outcome Measures

Primary Outcomes (3)

• Cutaneous Tolerance

  The total irritancy score (Erythema score + Oedema score + Papules score + Vesicles score) for each subject from baseline to end of study as observed by the investigation Dermatologist.

  14 Days

• Parental Assessment of Cutaneous Tolerance

  The dermatologist will ask the parent/legal guardian to provide their assessment of tolerance by asking the parent/legal guardian if they considered the product to be well tolerated by their child/baby's skin

  14 Days

• Global Assessment of Cutaneous Tolerance

  The dermatologist will make a 'global assessment' of tolerance for each subject based on reported product use/compliance

  14 Days

Study Arms (1)

E45 Eczema Repair Emollient

EXPERIMENTAL

Open label, single arm study to evaluate the skin tolerance of E45 Eczema Repair Emollient in babies and children

Device: E45 Eczema Repair Emollient

Interventions

E45 Eczema Repair Emollient DEVICE

E45 Eczema Repair Emollient

E45 Eczema Repair Emollient

Eligibility Criteria

• Age: 3 Months - 12 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• be female or male
• be a child aged from ≥3 years to \< 12 years or a baby aged from ≥3 months to \< 36 months at screening
• be phototype I - IV (Fitzpatrick Phototyping Scale)
• have skin that is dry/atopic or very dry/atopic (confirmed by the Dermatologist in consultation with the parent/legal guardian)
• have mild atopic eczema (as confirmed by the Dermatologist in consultation with the parent/legal guardian) but not undergoing steroid treatment for the condition
• have only few or no pigmentation on the selected test site
• be in general good health and mental condition
• In addition the parent/legal guardian must:
• Both parents in case of shared custody/legal guardian will provide written informed consent for their child/baby to participate in the investigation (children aged 6 years and above, capable of understanding the investigation after it has been explained to them, will be asked to provide assent. Pre-schoolers (2-5 years) will be allowed to express a level of assent verbally relating to their ability to do so)
• agree to attend the investigation centre, with the child/baby, on the predefined days
• be willing and capable to follow the investigation requirements

You may not qualify if:

• have chronic or acute skin diseases, except atopic eczema on any part of the body
• have an active flare up of atopic eczema on any sites of the body at screening
• known allergy or sensitivity to cosmetic products and/or any ingredients of the investigational product.
• any systemic illness that would impact on the subjects safety or wellbeing and/or affect the response of the skin or the interpretation of the test results at screening (Day -14 to -7)
• receiving the following topical or systemic treatments at baseline (Day 0);
• anti-inflammatory and/or anti-histamines during the previous week
• cough suppressants and/or topical or inhaled corticosteroids during the previous 2 weeks
• retinoids and/or immunosuppressants during the previous 6 months
• have diabetes, acute cardiac and circulatory diseases, HIV, hepatitis
• participation in other studies/investigations on any part of the body during the last 4 weeks
• use of dermatological therapeutics on the body within 7 days prior to baseline (Day 0) (use of such products on the face, trunk, hands and nappy area is permitted)
• swimming within 48 hours prior to baseline (Day 0)
• intensive/prolonged exposure to the sun within 30 days prior to screening
• planned changes to subject's diet during the investigation (e.g. weaning)
• subjects whose parent/legal guardian are employees or who work for a manufacturer of personal care products or for the testing facility

Sponsors & Collaborators

• Reckitt Benckiser Healthcare (UK) Limited: lead
• Intertek: collaborator

MeSH Terms

Conditions

Dermatitis, Atopic; Eczema

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Open label, in use tolerance study in babies and children.

Study Record Dates

• First Submitted: July 28, 2016
• First Posted: August 5, 2016
• Study Start: November 23, 2016
• Primary Completion: February 2, 2017
• Study Completion: February 2, 2017
• Last Updated: February 8, 2017

Record last verified: 2017-01

Data Sharing

• IPD Sharing: Will not share